ERBB2 and neoplasm: In an in vitro study on ErbB2/neu-overexpressing mouse mammary tumor NF639 and SMF cells, Pianetti et al. showed that EGCG decreased the phosphorylation and constitutive activation of ErbB2/neu, and suppressed the MAPK and NF-κB pathways, determining a sensible reduction of tumor growth [40].